MNTA Momenta Pharmaceuticals Inc.

14.1
+0.21  (+2%)
Previous Close 13.89
Open 13.87
Price To Book 3.01
Market Cap 1388978240
Shares 98,509,095
Volume 80,033
Short Ratio
Av. Daily Volume 602,248

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 trial to be completed 2019.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 2020.
M281
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
M281
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 dosing has commenced - noted January 29, 2019. Initial data due 1H 2020.
M254
Immune Thrombocytopenic Purpura (ITP)

Latest News

  1. Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
  2. See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.
  3. New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare — Consolidated Revenues, Company Growth, and Expectations for 2019
  4. Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
  5. Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
  6. Momenta (MNTA) Down 6.8% Since Last Earnings Report: Can It Rebound?
  7. Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta  
  8. How Should Investors React To Momenta Pharmaceuticals, Inc.’s (NASDAQ:MNTA) CEO Pay?
  9. Edited Transcript of MNTA earnings conference call or presentation 22-Feb-19 1:30pm GMT
  10. Momenta Continues to Rebuild
  11. Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat
  12. Momenta Pharmaceuticals (MNTA) Reports Q4 Loss, Tops Revenue Estimates
  13. Momenta: 4Q Earnings Snapshot
  14. Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  15. Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for
  16. Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast
  17. Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting